Etomidate Does Not Raise Seizure Threshold and May Actually Lower It
Etomidate does not elevate seizure threshold; in fact, evidence suggests it may lower the seizure threshold compared to other anesthetic agents, making it potentially pro-convulsant. This property has been specifically studied in the context of electroconvulsive therapy (ECT), where etomidate consistently produces longer seizure durations than propofol or methohexital 1, 2.
Evidence from Electroconvulsive Therapy Studies
The most direct evidence comes from ECT research, where seizure threshold is a critical clinical parameter:
Etomidate reduces the electrical stimulus dose needed to induce seizures. In seizure-resistant patients, switching from thiopental to etomidate decreased the required electrical stimulation from 638 to 497 millicoulombs (a 22% reduction), while simultaneously increasing seizure duration by 65% 2.
Etomidate produces significantly longer seizures than propofol. In schizophrenic patients undergoing ECT, etomidate resulted in EEG seizure durations of 49.6±23.1 seconds versus 39.7±19 seconds with propofol, despite no difference in the minimum seizure-eliciting stimulus energy between the two agents 1.
Multiple studies confirm etomidate's pro-convulsant properties. A 2026 systematic review analyzing 24 studies (11 RCTs and 13 observational studies) concluded that etomidate is more effective in prolonging seizure duration than propofol across various patient groups 3.
Clinical Implications
In Rapid Sequence Intubation and Sedation
The 2023 Society of Critical Care Medicine guidelines for RSI in critically ill adults make no mention of seizure concerns with etomidate, focusing instead on hemodynamic stability and adrenal suppression 4. The 2004 pediatric sedation guidelines similarly report no episodes of seizure activity in multiple retrospective studies of etomidate use 5.
Important Caveats
Myoclonus is not seizure activity. Etomidate commonly causes myoclonic movements (involuntary muscle jerks), which are reported in multiple studies 5, 6. These movements are not true seizures but rather subcortical disinhibition and should not be confused with lowered seizure threshold.
Context matters. The pro-convulsant effect is clinically relevant primarily in ECT settings where seizure induction is the goal. In standard anesthesia or sedation, this property does not translate to spontaneous seizure risk in patients without underlying seizure disorders.
Mechanism
According to the FDA label, etomidate is a GABA-potentiating agent that produces CNS depression 7. However, unlike propofol (which has more pronounced anticonvulsant properties), etomidate's specific pharmacologic profile appears to facilitate rather than suppress seizure activity when electrical stimulation is applied.
Bottom Line for Clinical Practice
If you need to avoid lowering seizure threshold (such as in patients with epilepsy or those at risk for seizures), etomidate is actually preferable to propofol or barbiturates, as it does not raise the seizure threshold and may even facilitate seizure activity. However, if you want to suppress seizure activity, choose propofol or benzodiazepines instead. The myoclonus commonly seen with etomidate should not be mistaken for true seizure activity and does not indicate a lowered seizure threshold in the pathological sense.